

# SINGLE NUCLEOTIDE POLYMORPHISM (SNP) GENOTYPING: TECHNOLOGIES AND GLOBAL MARKETS



**BIO139A**  
**September 2014**

Vijay Laxmi  
***Project Analyst***

ISBN: 1-56965-934-6



**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481 USA**  
**866-285-7215 (toll-free within the USA),**  
**or (+1) 781-489-7301**  
**[www.bccresearch.com](http://www.bccresearch.com)**  
**[information@bccresearch.com](mailto:information@bccresearch.com)**

**TABLE OF CONTENTS**

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
TITLE DESCRIPTION	2
SCOPE OF THE REPORT	3
MARKET STRUCTURE	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR SNP GENOTYPING, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR SNP GENOTYPING, 2013-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 MARKET OVERVIEW	11
INTRODUCTION	11
MARKET ANALYSIS	12
SNP FOR MUTATIONAL ANALYSIS	12
SNP DEFINITION	13
METHODS OF STUDYING SNPS	13
CLASSIFICATION OF SNPS:	13
USES OF SNPS:	14
MARKET DYNAMICS	14
DRIVERS	14
Decreasing Prices of DNA Sequencing	14
<i>FIGURE 1 AVERAGE PRICE YOY TRENDS OF A GENOME, 2003-2012 (\$)</i>	14
Growing Global Prevalence of Cardiovascular Disease, Diabetes and Cancer Triggering Demand for Developing Alternative and Relatively More Permanent Therapeutic Solutions	15
<i>FIGURE 2 PROJECTED PREVALENCE OF DIABETES, BY REGION, 2035 (% INCREASE OVER 2013)</i>	15
Growing Demand for Personalized Medicine and Growing Importance of SNP Genotyping in the Drug Development Process	16
<i>TABLE 1 USE OF SNP GENOTYPING DURING ALL THE STAGES OF DRUG DEVELOPMENT</i>	16
Increasing Demand for Genome Analysis in Animal and Plant Livestock	16
RESTRAINTS	17
Lack of Appropriate Reimbursement Policies	17
MARKET ATTRACTIVENESS BY REGION	17
NORTH AMERICA	17
<i>TABLE 2 LIST OF KEY ORGANIZATIONS FUNDING GENOMICS RELATED R &amp; D INITIATIVES IN THE U.S.</i>	18

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 3 COUNTRY OF ORIGIN OF PUBLICLY TRADED GENOMICS FIRMS (%)</i>	19
EUROPE	19
ASIA-PACIFIC	20
REST OF THE WORLD (ROW)	21
COMPETITIVE LANDSCAPE	21
INNOVATIONS AND CURRENT TRENDS	22
PUBLIC AND PRIVATE FUNDING	22
<i>TABLE 3 MAJOR PRIVATE AND PUBLIC FUNDING ORGANIZATIONS</i>	22
MARKET SHARE OF KEY PLAYERS	23
<i>FIGURE 4 COMPANY MARKET SHARE, 2013 (%)</i>	23
PATENT ANALYSIS	24
RECOMMENDATIONS	25
EXTENSIVE R&D INVESTMENTS	25
ACQUIRING EXTERNAL FUNDING	25
CONCLUSION	25
CHAPTER 4 GLOBAL SNP GENOTYPING MARKET BY TECHNOLOGY	28
OVERVIEW	28
<i>TABLE 4 SNP GENOTYPING MARKET, BY TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)</i>	29
SNP GENOTYPING BY MICROARRAYS AND GENECHIPS	29
ILLUMINA	29
AFFYMETRIX	30
FLUIDIGM	30
<i>TABLE 5 MICROARRAYS AND GENECHIPS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	31
SEQUENOM MASSARRAY MALDI-TOF	31
<i>TABLE 6 SEQUENOM MASSARRAY MALDI-TOF MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	32
SNP PYROSEQUENCING	32
<i>TABLE 7 SNP PYROSEQUENCING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	32
APPLIED BIOSYSTEMS SNPLEX	33
<i>TABLE 8 APPLIED BIOSYSTEMS SNPLEX MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	33
TAQMAN ALLELIC DISCRIMINATION	34
<i>TABLE 9 TAQMAN ALLELIC DISCRIMINATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	35
OTHER SNP GENOTYPING TECHNOLOGIES	35
<i>TABLE 10 OTHER SNP GENOTYPING TECHNOLOGIES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	36
CHAPTER 5 SNP GENOTYPING MARKET BY APPLICATIONS	38
OVERVIEW	38
<i>TABLE 11 GLOBAL SNP GENOTYPING MARKET BY APPLICATIONS, THROUGH 2019 (\$ MILLIONS)</i>	38
PLANT IMPROVEMENT	39
SNPS ARE IMPORTANT FOR INCREASING CROP YIELD	40
<i>TABLE 12 GLOBAL PLANT IMPROVEMNT MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	40

<b>TOPIC</b>	<b>PAGE NO.</b>
ANIMAL GENETICS	41
REDUCING COST OF SEQUENCING	42
IMPACT OF GENOMIC SELECTION IN ANIMALS	42
IMPLEMENTATION OF GENOMIC SELECTION	42
TRENDS	43
NEXT WAVE OF DISCOVERIES AND NEW APPROACHES	44
OPPORTUNITIES FOR DEVELOPING COUNTRIES	45
COST EFFECTIVENESS IN SEQUENCING WILL HELP FURTHER RESEARCH IN ANIMALS	45
<i>TABLE 13 GLOBAL ANIMAL GENETICS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	46
PHARMACEUTICALS AND PHARMACOGENOMICS	46
LINKAGE AND ASSOCIATION STUDIES	47
PHARMACEUTICAL APPLICATIONS	47
SNP ARRAYS ARE USEFUL TOOLS FOR THE KNOW-HOW OF EVEN SLIGHT DIFFERENCES AMONG WHOLE GENOMES	47
CONCLUSIONS	48
<i>TABLE 14 GLOBAL PHARMACEUTICALS AND PHARMACOGENOMICS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	49
DIAGNOSTIC RESEARCH	49
GENETIC RISK FACTORS	50
<i>TABLE 15 GLOBAL DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	51
AGRICULTURAL BIOTECHNOLOGY	51
CASE STUDY	52
CONCLUSION	52
<i>TABLE 16 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	53
AQUACULTURE	53
<i>TABLE 17 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	54
OTHERS (HUMAN IDENTITY TESTING, HUMAN FORENSICS, CONSERVATION)	54
<i>TABLE 18 GLOBAL OTHERS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	55
CHAPTER 6 SNP GENOTYPING MARKET BY REGION	57
OVERVIEW	57
NORTH AMERICA	57
<i>TABLE 19 NORTH AMERICA SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	58
EUROPE	58
<i>TABLE 20 EUROPE SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	59
ASIA-PACIFIC	59
<i>TABLE 21 ASIA-PACIFIC SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	61
REST OF WORLD (ROW)	61
<i>TABLE 22 ROW SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	62
CHAPTER 7 COMPETITIVE LANDSCAPE	64

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 5 STRATEGIES FOLLOWED IN THE SNP GENOTYPING MARKET BY KEY PLAYERS, 2011 TO APRIL 2014 (NUMBER)</i>	64
<i>TABLE 23 PRODUCT LAUNCHES IN SNP GENOTYPING MARKET, 2011-APRIL 2014</i>	65
<i>TABLE 24 JOINT VENTURES/ACQUISITIONS/AGREEMENTS IN THE SNP GENOTYPING MARKET, 2011-APRIL 2014</i>	70
<i>TABLE 25 CERTIFICATION AND RESEARCH &amp; DEVELOPMENT IN SNP GENOTYPING MARKET, 2011-APRIL 2014</i>	79
<i>TABLE 26 EXPANSION/REORGANIZATION/OTHERS IN SNP GENOTYPING MARKET, 2011-APRIL 2014</i>	81
<b>CHAPTER 8 COMPANY PROFILES</b>	<b>83</b>
<b>AFFYMETRIX INC.</b>	<b>83</b>
<i>TABLE 27 PRODUCT PORTFOLIO</i>	83
<i>TABLE 28 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	84
<b>AGILENT TECHNOLOGIES</b>	<b>86</b>
<i>TABLE 29 PRODUCT PORTFOLIO</i>	87
<i>TABLE 30 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	88
<b>BECKMAN COULTER</b>	<b>88</b>
<i>TABLE 31 PRODUCT PORTFOLIO</i>	89
<i>TABLE 32 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	89
<b>BIODISCOVERY</b>	<b>90</b>
<i>TABLE 33 PRODUCT PORTFOLIO</i>	90
<i>TABLE 34 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	91
<b>BIO-RAD LABORATORIES</b>	<b>92</b>
<i>TABLE 35 PRODUCT PORTFOLIO</i>	93
<i>TABLE 36 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	93
<b>COMBIMATRIX</b>	<b>94</b>
<i>TABLE 37 PRODUCT PORTFOLIO</i>	95
<i>TABLE 38 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	95
<b>DOUGLAS SCIENTIFIC</b>	<b>96</b>
<i>TABLE 39 PRODUCT PORTFOLIO</i>	96
<i>TABLE 40 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	97
<b>ENZO LIFE SCIENCES</b>	<b>97</b>
<i>TABLE 41 PRODUCT PORTFOLIO</i>	98
<i>TABLE 42 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	99
<b>EPIGENDX</b>	<b>99</b>
<i>TABLE 43 PRODUCT PORTFOLIO</i>	100
<i>TABLE 44 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	100
<b>FLUIDIGM CORP.</b>	<b>100</b>
<i>TABLE 45 PRODUCT PORTFOLIO</i>	101
<i>TABLE 46 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	102
<b>GE HEALTHCARE</b>	<b>103</b>
<i>TABLE 47 PRODUCT PORTFOLIO</i>	104
<i>TABLE 48 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	104
<b>ILLUMINA INC.</b>	<b>105</b>
<i>TABLE 49 PRODUCT PORTFOLIO</i>	106
<i>TABLE 50 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	107
<b>LI-COR BIOSCIENCES</b>	<b>109</b>

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 51 PRODUCT PORTFOLIO</i>	109
<i>TABLE 52 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	110
LIFE TECHNOLOGIES (A BRAND OF THERMO FISHER SCIENTIFIC)	110
<i>TABLE 53 PRODUCT PORTFOLIO</i>	111
<i>TABLE 54 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	111
OCIMUM BIOSOLUTIONS	112
<i>TABLE 55 PRODUCT PORTFOLIO</i>	112
<i>TABLE 56 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	113
PREMIER BIOSOFT	113
<i>TABLE 57 PRODUCT PORTFOLIO</i>	113
<i>TABLE 58 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	114
QIAGEN	114
<i>TABLE 59 PRODUCT PORTFOLIO</i>	115
<i>TABLE 60 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	115
ROCHE	117
<i>TABLE 61 PRODUCT PORTFOLIO</i>	117
<i>TABLE 62 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	118
SEQUENOM INC.	118
<i>TABLE 63 PRODUCT PORTFOLIO</i>	119
<i>TABLE 64 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	119
SIGMA-ALDRICH	119
<i>TABLE 65 PRODUCT PORTFOLIO</i>	120
<i>TABLE 66 RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	120
CHAPTER 9 PATENT ANALYSIS	123
<i>FIGURE 6 PATENTS BY REGION, 2011-JUNE 2014 (NUMBER)</i>	123
<i>TABLE 67 U.S. PATENTS, 2011-JUNE 2014</i>	124
<i>TABLE 68 EUROPEAN PATENTS, 2011-JUNE 2014</i>	129
<i>TABLE 69 JAPANESE PATENTS, 2011-JUNE 2014</i>	132

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR SNP GENOTYPING, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 USE OF SNP GENOTYPING DURING ALL THE STAGES OF DRUG DEVELOPMENT	16
TABLE 2 LIST OF KEY ORGANIZATIONS FUNDING GENOMICS RELATED R & D INITIATIVES IN THE U.S.	18
TABLE 3 MAJOR PRIVATE AND PUBLIC FUNDING ORGANIZATIONS	22
TABLE 4 SNP GENOTYPING MARKET, BY TECHNOLOGIES, THROUGH 2019 (\$ MILLIONS)	29
TABLE 5 MICROARRAYS AND GENECHIPS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	31
TABLE 6 SEQUENOM MASSARRAY MALDI-TOF MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	32
TABLE 7 SNP PYROSEQUENCING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	32
TABLE 8 APPLIED BIOSYSTEMS SNPlex MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	33
TABLE 9 TAQMAN ALLELIC DISCRIMINATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	35
TABLE 10 OTHER SNP GENOTYPING TECHNOLOGIES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	36
TABLE 11 GLOBAL SNP GENOTYPING MARKET BY APPLICATIONS, THROUGH 2019 (\$ MILLIONS)	38
TABLE 12 GLOBAL PLANT IMPROVEMNT MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	40
TABLE 13 GLOBAL ANIMAL GENETICS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	46
TABLE 14 GLOBAL PHARMACEUTICALS AND PHARMACOGENOMICS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	49
TABLE 15 GLOBAL DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	51
TABLE 16 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	53
TABLE 17 GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	54
TABLE 18 GLOBAL OTHERS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	55
TABLE 19 NORTH AMERICA SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)	58
TABLE 20 EUROPE SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)	59
TABLE 21 ASIA-PACIFIC SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)	61
TABLE 22 ROW SNP GENOTYPING TECHNOLOGIES MARKET, THROUGH 2019 (\$ MILLIONS)	62
TABLE 23 PRODUCT LAUNCHES IN SNP GENOTYPING MARKET, 2011-APRIL 2014	65
TABLE 24 JOINT VENTURES/ACQUISITIONS/AGREEMENTS IN THE SNP GENOTYPING MARKET, 2011-APRIL 2014	70
TABLE 25 CERTIFICATION AND RESEARCH & DEVELOPMENT IN SNP GENOTYPING MARKET, 2011-APRIL 2014	79
TABLE 26 EXPANSION/REORGANIZATION/OTHERS IN SNP GENOTYPING MARKET, 2011-APRIL 2014	81
TABLE 27 PRODUCT PORTFOLIO	83

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 28 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	84
TABLE 29 PRODUCT PORTFOLIO	87
TABLE 30 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	88
TABLE 31 PRODUCT PORTFOLIO	89
TABLE 32 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	89
TABLE 33 PRODUCT PORTFOLIO	90
TABLE 34 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	91
TABLE 35 PRODUCT PORTFOLIO	93
TABLE 36 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	93
TABLE 37 PRODUCT PORTFOLIO	95
TABLE 38 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	95
TABLE 39 PRODUCT PORTFOLIO	96
TABLE 40 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	97
TABLE 41 PRODUCT PORTFOLIO	98
TABLE 42 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	99
TABLE 43 PRODUCT PORTFOLIO	100
TABLE 44 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	100
TABLE 45 PRODUCT PORTFOLIO	101
TABLE 46 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	102
TABLE 47 PRODUCT PORTFOLIO	104
TABLE 48 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	104
TABLE 49 PRODUCT PORTFOLIO	106
TABLE 50 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	107
TABLE 51 PRODUCT PORTFOLIO	109
TABLE 52 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	110
TABLE 53 PRODUCT PORTFOLIO	111
TABLE 54 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	111
TABLE 55 PRODUCT PORTFOLIO	112
TABLE 56 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	113
TABLE 57 PRODUCT PORTFOLIO	113
TABLE 58 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	114
TABLE 59 PRODUCT PORTFOLIO	115
TABLE 60 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	115
TABLE 61 PRODUCT PORTFOLIO	117
TABLE 62 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	118
TABLE 63 PRODUCT PORTFOLIO	119
TABLE 64 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	119
TABLE 65 PRODUCT PORTFOLIO	120
TABLE 66 RECENT DEVELOPMENTS, 2011 TO APRIL 2014	120
TABLE 67 U.S. PATENTS, 2011-JUNE 2014	124
TABLE 68 EUROPEAN PATENTS, 2011-JUNE 2014	129
TABLE 69 JAPANESE PATENTS, 2011-JUNE 2014	132



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR SNP GENOTYPING, 2013-2019 (\$ MILLIONS)	8
FIGURE 1 AVERAGE PRICE YOY TRENDS OF A GENOME, 2003-2012 (\$)	14
FIGURE 2 PROJECTED PREVALENCE OF DIABETES, BY REGION, 2035 (% INCREASE OVER 2013)	15
FIGURE 3 COUNTRY OF ORIGIN OF PUBLICLY TRADED GENOMICS FIRMS (%)	19
FIGURE 4 COMPANY MARKET SHARE, 2013 (%)	23
FIGURE 5 STRATEGIES FOLLOWED IN THE SNP GENOTYPING MARKET BY KEY PLAYERS, 2011 TO APRIL 2014 (NUMBER)	64
FIGURE 6 PATENTS BY REGION, 2011-JUNE 2014 (NUMBER)	123